Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
24.40
-0.56 (-2.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,073,154
Open
24.83
Bid (Size)
24.40 (64)
Ask (Size)
24.41 (1)
Prev. Close
24.96
Today's Range
24.32 - 25.06
52wk Range
21.62 - 44.32
Shares Outstanding
160,500,999
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 08, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BBIO Stock Earnings: BridgeBio Pharma Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
BBIO stock results show that BridgeBio Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-39.68%
-39.68%
1 Month
-12.83%
-12.83%
3 Month
-18.91%
-18.91%
6 Month
-34.43%
-34.43%
1 Year
-14.11%
-14.11%
More News
Read More
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
August 01, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
July 23, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Why BridgeBio Pharma Stock Is Trading Lower Tuesday
June 04, 2024
Via
Benzinga
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
June 24, 2024
Via
Benzinga
Masters In Trading - Saturday, June 22
June 22, 2024
Via
Talk Markets
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
June 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 12, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
June 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 05, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
The 3 Best Biotech Stocks to Buy in June 2024
June 05, 2024
Via
InvestorPlace
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
June 04, 2024
Via
Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
June 04, 2024
Via
Investor's Business Daily
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
June 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
June 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
May 29, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Via
InvestorPlace
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
May 24, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
May 14, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
May 13, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.